The Cardiometabolic Serum Test is more advanced than a standard screen for cardiovascular disease (CVD) risk factors. The test includes much more clinically sensitive atherogenic lipoprotein sub-species, the primary apolipoproteins, arterial inflammation and the activity of the lipoprotein- associated phospholipase- A2 (PLAC). PLAC activity is a sensitive indicator of active atherogenesis and instability of advanced arterial plaque. The test also includes cystatin C to better assess glomerular filtration, and 1,5-anhydroglucitol (Glycomark®) that is a better indicator of hyperglycaemic episodes than HbA1C. The primary adipokines associated with insulin sensitivity and hepatic fatty acid metabolism are also addressed. This test is useful for those with a family or personal history, excess abdominal fat, obesity, insulin resistance and fatty liver disease. It can also be used for preventative purposes in asymptomatic patients.